Freidy Eid, MD
Cardiovascular Disease · Wichita, KSNPI 1629205356
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,479 of the $12,501 with a category attached, or 75.8%. 27 manufacturers reported payments, led by Abbott at 44.8% of the total. Reporting peaked in 2024 at $4,088 and has fallen 85.0% since, to $613 in 2025. Among cardiovascular disease clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $49.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Medtronic$4K
- Boehringer Ingelheim$660
- AstraZeneca$517
- E.r. Squibb & Sons, L.L.C.$299
- Cvrx, Inc.$214
- plus $1K from 21 others
What the payments were for
- Travel & lodging$2,98124%
- Food & beverage$9,47976%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 80 | $5,603 |
| Medtronic(2 entities) | 44 | $3,763 |
| Boehringer Ingelheim | 23 | $660 |
| AstraZeneca | 35 | $517 |
| E.r. Squibb & Sons, L.L.C. | 7 | $299 |
| Cvrx, Inc. | 3 | $214 |
| Boston Scientific | 6 | $208 |
| Sanofi-aventis U.S. LLC | 6 | $194 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $171 |
| Novartis | 7 | $159 |
| Philips North America LLC | 2 | $103 |
| Biotronik Inc. | 5 | $95 |
| Pfizer | 6 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $78 |
| Novo Nordisk | 3 | $63 |
| Amgen | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $45 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Merck | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Surmodics, Inc. | 3 | $23 |
| Bayer | 1 | $20 |
| Edwards Lifesciences | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,270
- Micra$1,804
- Confirm Rx$505
- CardioMEMS HF System$357
- JARDIANCE$343
- ASSURITY$269
- MitraClip System$146
- Durata Defibrillation ICD Lead$141
- ARCALYST$135
- PRESSUREWIRE$135
- PRALUENT$125
- CAMZYOS$125
- ALLURE QUADRA$123
- JOT DX$122
- Barostim Neo System$111
- Watchman$108
- CARDIOMEMS$107
- Cobalt$105
How this compares
$12,501 in reported general payments places this provider in the 90th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 550 | $408,944 |
| EntrestoSacubitril/Valsartan | 240 | $199,656 |
| JardianceEmpagliflozin | 210 | $143,360 |
| XareltoRivaroxaban | 80 | $65,701 |
| FarxigaDapagliflozin Propanediol | 60 | $50,249 |
| BrilintaTicagrelor | 24 | $13,054 |
| Repatha SureclickEvolocumab | 18 | $12,086 |
| Praluent PenAlirocumab | 11 | $5,387 |
| Midodrine Hcl | 33 | $2,246 |
| Bumetanide | 81 | $2,117 |
| Metoprolol Succinate | 270 | $1,931 |
| Ezetimibe | 112 | $1,882 |
| Amiodarone Hcl | 184 | $1,758 |
| Atorvastatin Calcium | 332 | $1,636 |
| Potassium Chloride | 169 | $1,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $408,944550 claims |
| NovartisEntresto | $159 | $199,656240 claims |
| Boehringer IngelheimJardiance | $660 | $143,360210 claims |
| AstraZenecaFarxiga, Brilinta | $517 | $63,30384 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Mohamad FarhatWichita$11K
- Thomas AshcomWichita$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.